



Monitoring protein conformational changes using fluorescent nanoantennas

Scott G. Harroun¹, Dominic Lauzon¹, Maximilian C. C. J. C. Ebert², Arnaud Desrosiers^{1,3}, Xiaomeng Wang¹ and Alexis Vallée-Bélisle^{1,3} ✉

Understanding the relationship between protein structural dynamics and function is crucial for both basic research and biotechnology. However, methods for studying the fast dynamics of structural changes are limited. Here, we introduce fluorescent nanoantennas as a spectroscopic technique to sense and report protein conformational changes through noncovalent dye-protein interactions. Using experiments and molecular simulations, we detect and characterize five distinct conformational states of intestinal alkaline phosphatase, including the transient enzyme-substrate complex. We also explored the universality of the nanoantenna strategy with another model protein, Protein G and its interaction with antibodies, and demonstrated a rapid screening strategy to identify efficient nanoantennas. These versatile nanoantennas can be used with diverse dyes to monitor small and large conformational changes, suggesting that they could be used to characterize diverse protein movements or in high-throughput screening applications.

Experimental study of protein transient states¹ remains a major challenge because high-structural-resolution techniques, including nuclear magnetic resonance and X-ray crystallography, often cannot be directly applied to study short-lived protein states. In contrast, high-temporal-resolution fluorescence spectroscopy is better suited to detect transient states^{2,3}, in addition to being convenient, highly sensitive and widely available. While large conformational changes can often be detected using intrinsic tryptophan fluorescence⁴, those in the ~3–9 nm range are typically detected using Förster resonance energy transfer (FRET). FRET, however, requires the complicated chemistry of site-specific insertion of fluorophores^{5,6}. Thus, despite much progress in fluorescence techniques^{7–10}, there remains an unmet need for sensitive strategies that are able to detect the small conformational changes¹¹ experienced by some proteins during their function, such as enzyme catalysis¹², as well as for simpler and more efficient labeling strategies.

Here, we report the design, engineering and application of a versatile tool called fluorescent nanoantennas, which sense and report protein conformational change, and in turn protein function, in real time. Since widely available fluorescent dyes display low affinity for proteins^{13,14}, these nanoantennas are designed to drive noncovalent dye-protein interactions, making them highly sensitive to conformational changes. Each dye ought to have an affinity for a different region of a protein, depending on their structural complementarity and chemical properties. Thus, via highly programmable phosphoramidite chemistry, we synthesized nucleic acid (DNA) and polyethylene glycol (PEG) nanoantennas containing dyes and other functional modifications. We also leveraged the convenience of biotin-streptavidin (SA) noncovalent interaction, which enables quick and easy connection of biotin-labeled nanoantennas to biotin-labeled proteins.

As a first model protein to test whether nanoantennas can detect protein activity, we selected calf intestinal alkaline phosphatase (AP; EC 3.1.3.1)¹⁵. The study of intestinal AP is an active area of research¹⁶ due to its important roles in preventing inflammation¹⁷, promoting

growth of the commensal microbiota¹⁸, regulating pH¹⁹, activating prodrugs^{20,21} and studies of fundamental biophysics²². APs have been implicated in breast, prostate, colorectal and gastric cancers^{23–26}, metabolic syndrome²⁷, hypophosphatasia^{28,29}, myocardial infarction³⁰, chronic intestinal inflammation³¹ and even SARS-CoV-2 infection³². This enzyme has been characterized by crystallography^{33–35}, computational simulations³⁶, unfolding³⁷, inhibitors^{38,39}, mutations⁴⁰ and hydrolysis of substrates^{40,41}. Classic^{42,43} and newer strategies^{44–46} to characterize AP-mediated hydrolysis in real time involve monitoring the rate of product generation (Extended Data Fig. 1). Unfortunately, these assays require synthetic substrates to provide a signal, whereas biomolecular substrates of AP are spectroscopically silent (for example, nucleotide triphosphates)^{18,19}. For biomolecules, the standard malachite green assay does not permit real-time analysis⁴⁷, while alternative biomolecular assays are not universal^{48,49}. Isothermal titration calorimetry^{50,51} can characterize AP activity for biological substrates⁵², but it is not amenable to high-throughput screening. We are not aware of any FRET studies involving labeling of AP, presumably due to the small conformational changes experienced by this protein^{34,53}. Here, we designed fluorescent nanoantennas, investigated their signaling mechanism and applied them to study AP function as well as a second protein system, Protein G interacting with various antibodies⁵⁴.

Results

Mechanism of fluorescent nanoantennas. We summarize the general idea of our strategy in Fig. 1a. The DNA- or PEG-based fluorescent nanoantennas contain a fluorescent dye at one end, such as fluorescein (FAM), and biotin at the other to facilitate attachment (Start). Using biotin, we attached the nanoantenna to wild-type tetrameric SA from *Streptomyces avidinii*, which has four biotin-binding sites, and observed a decrease (or quenching) in FAM fluorescence (Step 1). Docking simulations (Fig. 1b), experimental evidence (Extended Data Fig. 2) and previous studies^{55,56} suggest that FAM binds near the unoccupied biotin-binding

¹Laboratoire de Biosenseurs & Nanomachines, Département de chimie, Université de Montréal, Montréal, Québec, Canada. ²Chemical Computing Group ULC, Montréal, Québec, Canada. ³Département de biochimie et médecine moléculaire, Université de Montréal, Montréal, Québec, Canada. ✉e-mail: a.vallee-belisle@umontreal.ca




Fig. 1 | Overview of the fluorescent nanoantenna strategy to probe different regions on a protein. **a**, Cartoon and example data of fluorescent nanoantennas. For simplicity, the cartoon shows only one of each component. a.u., arbitrary units. **b**, The docking simulation accurately predicts the binding sites of biotin on SA and the substrate pNPP on AP. **c**, Docking prediction of the dyes FAM, CAL and Cy3 on SA and AP. **d–i**, Optimization of the length (**d**) and composition (**e**) of the linker for Step 1 and similarly for Step 2 (length, **f**; composition, **g**). See Supplementary Fig. 1 for corresponding fluorescence spectra. Similar results (length, **h**; composition, **i**) were observed for the fluorescence spike during hydrolysis of pNPP for Step 3. For **d–i**, $n = 1$ biologically independent enzyme samples were examined over three independent experiments. Data are presented as mean values \pm s.e.m. **j–l**, Kinetic signatures of ssDNA nanoantennas (NA) containing the dye FAM ($\lambda_{\text{ex}} = 498$ nm, $\lambda_{\text{em}} = 520$ nm) (**j**), CAL ($\lambda_{\text{ex}} = 540$ nm, $\lambda_{\text{em}} = 561$ nm) (**k**) or Cy3 ($\lambda_{\text{ex}} = 546$ nm, $\lambda_{\text{em}} = 563$ nm) (**l**) for SA and bAP binding events, as well as pNPP hydrolysis. fluor., fluorescence. **m, n**, Double-dye competition kinetic signatures for FAM (**m**) and CAL (**n**). In **m**, the data at the top show the monitoring of FAM fluorescence of a single-dye dsDNA nanoantenna with FAM, and the data at the bottom show the monitoring of FAM fluorescence of a double-dye dsDNA nanoantenna with FAM and CAL. In **n**, the data at the top show the monitoring of the CAL fluorescence of a single-dye dsDNA nanoantenna with CAL, and the data at the bottom show the monitoring of the CAL fluorescence of a double-dye dsDNA nanoantenna with FAM and CAL.

sites of SA. Next, we added the model protein, biotinylated calf intestinal alkaline phosphatase (bAP). Unlike specific dye labeling required for FRET experiments, our method employed nonspecific biotinylation, which can be performed conveniently on many proteins without affecting their function⁵⁷. Binding of bAP to the

nanoantenna-SA platform results in an increase in the fluorescence signal (Step 2), suggesting that FAM is released from SA. Upon addition of a substrate of AP, the nanoantenna generates a transient fluorescence ‘spike’ (Step 3), enabling real-time monitoring of the enzyme’s transient substrate-bound state. This result, combined




Fig. 2 | Fluorescent nanoantennas enable complete characterization of the enzyme's kinetic mechanism. **a**, Increasing the substrate concentration increases the fluorescence spike intensity and duration, displaying a profile reminiscent of the enzyme–substrate concentration ($[ES]$) during a typical enzymatic reaction. **b**, Fluorescence intensity is correlated with the rate of reaction (and $[ES]$) determined by monitoring pNP generation via UV–visible spectroscopy. **c**, The saturation binding curve realized using the nanoantenna spike intensity displays a typical Michaelis–Menten-like plot. **d**, Nanoantenna-labeled enzyme allows sequential injection of pNPP without signal saturation. Here, subsequent pNPP injection ($30\ \mu\text{M}$) results in prolonged reaction time and reduced spike intensity due to competitive inhibition via the accumulation of P_i . **e**, Extracting K_M and k_{cat} using the fluorescent nanoantenna signature of a single reaction (See Methods, Supplementary Fig. 25 and ‘Script for fitting kinetic data in MATLAB’ in the Supplementary Information for details of the fitting procedure). **f**, Extracting K_i using the fluorescent nanoantenna signature of multiple reactions. All experiments were performed with $n=1$ biologically independent enzyme samples examined over three independent experiments. Data are presented as mean values \pm s.e.m. In **a–c**, we used $100\ \text{nM}$ BAP from a commercially available sample, and in **d–f** we used $10\ \text{nM}$ BAP prepared by us from AP and a biotinylation kit.

with docking simulations (Fig. 1c), suggests that FAM binds near one of the two equivalent active sites.

We explored how the nanoantenna linker length (LX, where X is the number of nucleotides) (Fig. 1d) and composition (Fig. 1e) impact dye–protein interactions. As a ‘no linker’ L0 nanoantenna, we selected a biotin–fluorescein conjugate. Upon binding to SA, its fluorescein moiety is located just outside the biotin-binding site that it occupies⁵⁸. This short nanoantenna displayed substantial fluorescence quenching. Using single-stranded DNA (ssDNA), we increased the linker length to L6 or L12, thereby enabling FAM to interact with more of the SA surface. These nanoantennas displayed moderate quenching, with their FAMs likely binding near unoccupied biotin-binding sites (Fig. 1b)^{55,56}. The longer L24 and L48 nanoantennas displayed reduced quenching, consistent with fewer dyes being bound to the protein due to the lower effective concentration of the dye near SA. We also tried a more flexible, hydrophilic and less charged PEG-based nanoantenna (approximately L21, Supplementary Fig. 2), which displayed increased quenching. In contrast, a less flexible double-stranded DNA (dsDNA) L24 nanoantenna prevented the FAM–SA interaction.

Linker length (Fig. 1f) and composition (Fig. 1g) likewise affected the monitoring of protein binding to SA. As expected, due to its short length, L0 did not detect bAP. The longer L6 and especially L12 nanoantennas enabled FAM to detect bAP attachment, but L24 and especially L48 were too long to result in a high local concentration of FAM near bAP. Also as expected, we observed that a PEG linker enabled good FAM–bAP interaction, while a less flexible

dsDNA linker did not. A molecular dynamics (MD) simulation with the optimal L12 nanoantenna revealed that its FAM could plausibly reach the bound bAP, supporting our hypothesis regarding the dye–enzyme interaction (Extended Data Fig. 3 and Supplementary Video 1). We have additionally explored other factors, such as pH variation and the ratio of components, and found that PEG linkers were less sensitive to pH variation (Supplementary Fig. 3), while using too many nanoantennas per streptavidin diminishes signaling by preventing enzyme attachment (Supplementary Figs. 4–6).

We next investigated the mechanism by which the nanoantennas generated a transient fluorescence spike during hydrolysis of *p*-nitrophenylphosphate (pNPP; step 3 in Fig. 1a). As expected, the most sensitive nanoantennas for probing bAP attachment were also the most sensitive for probing its catalytic activity (Fig. 1h,i and Supplementary Fig. 7). The stoichiometry of the added components is important; we found that adding three nanoantennas per SA maximizes signal without potentially limiting the ability of the biotinylated enzyme to bind to the remaining unoccupied biotin-binding site(s). Nanoantenna size, and therefore steric hindrance⁵⁹, is also a factor (Supplementary Fig. 7d). As controls, we noted that no spike occurred when there was no hydrolysis reaction, for example, upon addition of the reaction products (Extended Data Fig. 4a–c) or upon addition of pNPP when unattached non-biotinylated nanoantennas were employed (Extended Data Fig. 4d). We also did not observe a signal change due to intrinsic tryptophan fluorescence (Supplementary Fig. 8)⁴, and could not detect AP function with the protein-binding dye 8-anilino-1-naphthalene-1-sulfonic




Fig. 3 | Fluorescent nanoantennas enabled real-time monitoring of any substrate hydrolyzed by AP. Nanoantenna fluorescence signatures during hydrolysis of pNPP, 4MUP, PP_i, BGP, PEP, PSer, PLP, G6P, F6P, AMP, ADP, ATP, GTP, PCr and amifostine (all 300 μM). All experiments were performed with $n=1$ biologically independent enzyme samples examined over three independent experiments. Data are presented as mean values ± s.e.m.

acid (Supplementary Fig. 9)⁶⁰. We did, however, observe a spike with other nanoantenna attachment strategies (for example, covalent attachment to surface-exposed lysine residues of AP; Extended Data Fig. 4e–h), different buffer conditions (Supplementary Fig. 10) and various storage times (Supplementary Fig. 11). We also observed that the intensity of the nanoantenna's fluorescence in the different states (that is, after addition of SA, bAP and pNPP) was sensitive to small chemical modifications that could subtly perturb the FAM-protein interaction, such as a nearby hydrophobic C₁₆ alkane chain (Extended Data Fig. 5) and different chemical connections of FAM to the linker (Extended Data Fig. 6). Finally, under some conditions, we observed that the fluorescence spike intensity during pNPP hydrolysis was greater than the initial fluorescence of the unbound nanoantenna (Fig. 1j and Supplementary Fig. 12). FAM simply being ejected from the active site by the incoming pNPP substrate would likely just return the fluorescence to the initial

baseline before protein binding. Overall, these results reinforce our proposed mechanism that the nanoantenna-mediated dye-enzyme interaction enables monitoring of the conformational changes on the enzyme's surface during its function.

The testing of chemically diverse dyes on ssDNA L12 nanoantennas provides information about the signaling mechanism and potential universality of the strategy. Different dyes are predicted to bind to different sites on AP (Fig. 1c and Supplementary Figs. 13 and 14). Interestingly, all nine dyes tested enabled monitoring of the SA and bAP binding events, albeit weakly in some cases. Shown here are FAM, the rhodamine-based CAL Fluor Orange 560 (CAL) and cyanine 3 (Cy3) (Fig. 1j–l; see other dyes in Supplementary Fig. 15a–i). In contrast to FAM, Cy3 shows increased fluorescence upon binding to SA and decreased fluorescence upon binding to bAP⁷, and it is more sensitive with a dsDNA linker. However, similar to FAM, it is affected by its chemical connection (Supplementary Fig. 15e,f).




Fig. 4 | Screening inhibitors by monitoring AP hydrolysis using fluorescent nanoantennas. The inhibitory effects on AP of phosphate, molybdate, tungstate, arsenate and vanadate, as well as the effect of Mg^{2+} ion (black) with the substrate amifostine. Kinetic fitting of the data is overlaid (pink). Shown also for comparison is the hydrolysis of amifostine without inhibitor (gray). The baseline of the kinetic signature without the effector was adjusted for presentation of data (that is, due to the fluorescence quenching caused by vanadate and magnesium ion). All experiments were performed with $n = 1$ biologically independent enzyme samples examined over three independent experiments. Data are presented as mean values \pm s.e.m. In all experiments, we used $30 \mu M$ inhibitor or $5 \text{ mM } Mg^{2+}$, and otherwise the same conditions as in Fig. 3.

We also found that the kinetics of the signal change upon addition of bAP depend both on the concentration of bAP (Supplementary Fig. 16) and on the nanoantenna properties (Supplementary Fig. 17). This suggests that dye dissociation from SA is not rate limiting and that the dye-binding location and the nature of the linker may affect the rate at which bAP binds to SA (for example, through steric hindrance). We further observed that nanoantennas with FAM, CAL and Cy3 enabled monitoring of pNPP hydrolysis. Crucially, while the three dyes provided different sensitivities toward the functional events, they all exhibited the same kinetics for pNPP hydrolysis (Supplementary Fig. 15j), indicating that the dye-protein interactions exploited herein did not interfere with protein function. From a practical perspective, FAM remains the best dye for monitoring AP function. However, from a mechanistic perspective, the other dyes provide strong evidence that nanoantennas employing chemically diverse dyes can be used to probe conformational changes at different locations.

We investigated the signaling mechanisms of dyes predicted to bind at different locations. For nanoantennas with FAM, we proposed three mechanisms for modulation of fluorescence during AP function: (1) binding of pNPP at the active site directly ejects FAM from its nearby binding site; (2) small conformational changes alter FAM's affinity for AP and release it from the binding site; or (3) small conformational changes perturb the emission of the bound FAM. For CAL and Cy3, which are predicted to bind at locations distal to the active site, we proposed only the latter two mechanisms. Thus we used MD simulations and examined the trajectories of the bound dyes in the presence or absence of bound pNPP (Extended Data Fig. 7). FAM remained bound near the active site both in the absence and in the presence of pNPP, suggesting a strong affinity for this site. In contrast, CAL was not stabilized in its initial binding site in either the absence or presence of pNPP, suggesting low affinity. Interestingly, Cy3 remained bound in the absence of pNPP

but dissociated in its presence. These simulations, therefore, suggest a FAM-signaling mechanism that is not based on ejection by pNPP nor a change in affinity, but instead by the sensing of small conformational changes in the local chemical environment^{61,62}. For CAL, the mechanism remains uncertain, but for Cy3, the simulations suggest that conformational changes during pNPP hydrolysis transiently release the dye. The bound and unbound states of Cy3 could, for example, affect its *cis-trans* isomerism and therefore its fluorescence^{7,63,64}.

If the sensitivity of a nanoantenna truly depends on whether the dye's binding location experiences conformational change during protein function, one ought to observe a change in the fluorescence signature upon forcing the dye to bind at another location. To test this hypothesis, we employed a dsDNA L12 nanoantenna containing both FAM and CAL (Fig. 1m,n). Our reasoning was that the two dyes will compete for their preferred binding sites on bAP. On the basis of the above MD simulations, we expected that the higher affinity FAM will bring the lower affinity CAL along with it. Aside from the decrease of signal intensity, likely due to a contact-mediated quenching mechanism between the dyes⁶⁵ (Extended Data Fig. 8), we observed that the presence of CAL does not substantially affect the FAM fluorescent signature (Fig. 1m). In contrast, the addition of FAM substantially affects the CAL fluorescent signature (Fig. 1n). Notably, it now enables CAL to efficiently detect the conformational change of the protein during pNPP hydrolysis (Fig. 1n). Given that CAL likely stacks on FAM (Extended Data Fig. 8), it is plausible that the fluorescent change of CAL is triggered by the same conformational change affecting the FAM dye. Importantly, the presence of the second dye did not affect the kinetics of the substrate hydrolysis (Supplementary Fig. 18a). We also found that employing FAM with other dyes led to similar results (Supplementary Fig. 18b,c). Of note, these changes in the fluorescence signature do not arise due to FAM emitting a signal that overlaps with the




Fig. 5 | Detecting other states of AP using fluorescent nanoantennas. **a**, Five distinct states of AP detected during enzymatic reaction and denaturation. First, the enzyme (E) is present in solution, followed by the energetically favorable binding of a substrate (for example, pNPP) to form an ES complex. Next, the high-energy transition state (ES[‡]) is formed. This state cannot be observed directly but can be studied via TSA inhibitors that mimic its geometry, such as V_i. Since V_i is a competitive inhibitor, it also represents an enzyme–inhibitor complex (not shown). After the hydrolysis of pNPP, the bound P_i product (EP) is released from the enzyme (E + P). As a competitive inhibitor, P_i can rebind to the active site. AP can also be unfolded by thermal denaturation (E^{unfolded}). **b**, Unlike the spike during pNPP hydrolysis, V_i binding quenches the nanoantenna’s fluorescence. **c**, Binding curve of the nanoantenna-SA-bAP complex sensing V_i (blue) and W_i (orange). Other competitive inhibitor oxyanions do not exhibit a substantial fluorescence change. **d**, Thermal shift assay of the nanoantenna (gray), nanoantenna-SA platform (light green) and nanoantenna-SA-bAP complex (violet). **e**, Smoothing of the derivatives (black lines) reveals no transition for the unbound nanoantennas, but does for the nanoantenna-SA platform and nanoantenna-SA-bAP complex. In **c–e**, all experiments were performed with $n=1$ biologically independent enzyme samples examined over three independent experiments. Data are presented as mean values \pm s.e.m.

excitation wavelengths of other dyes (Supplementary Fig. 18d,e). Thus, these experiments provide strong evidence that FAM can redirect other dyes to a location proximal to its own binding site on AP. This observation is consistent with the aforementioned MD simulations, suggesting that FAM is more tightly bound than Cy3 and CAL to AP (Extended Data Fig. 7). Hypothetically, one could rationally employ other non-dye ‘molecular anchors’ to redirect dyes to specific locations on proteins, as FAM does for CAL on AP.

Characterizing enzyme kinetics. Nanoantennas can be used to characterize the kinetic mechanisms of enzymes. By employing ssDNA L12 FAM nanoantennas hereafter, we first observed that the addition of more pNPP increased the spike intensity and duration (Fig. 2a). The resulting fluorescence signature is reminiscent of the expected profile of the enzyme–substrate concentration ([ES]) during a typical enzymatic reaction (Extended Data Fig. 1b). The signal rapidly peaked and then maintained a steady state until the substrate began to run out. This hypothesis is consistent with the nanoantennas distinguishing between the enzyme and enzyme–substrate conformations. We confirmed the link between the fluorescence intensity of the spike and [ES] by showing that the former is proportional to the rate of reaction obtained by monitoring *p*-nitrophenol (pNP) generation via UV–visible spectroscopy (Fig. 2b). Indeed,

plotting the spike intensity versus pNPP concentration generated a saturation binding curve that is reminiscent of a Michaelis–Menten plot (Fig. 2c; Supplementary Fig. 19). Fitting the data provided a $K_{0.5}$ value that is similar to the Michaelis constant (K_M) reported in the literature under the same conditions ($K_{0.5} = 4.4 \pm 0.2 \mu\text{M}$; Supplementary Fig. 20)⁵².

Nanoantennas enable complete kinetic characterization of an enzyme in a single experiment. Unlike the monitoring of AP kinetics by product generation^{42–44}, one enzyme sample with nanoantennas can enable multiple measurements in one cuvette. This could be used to characterize various substrates or inhibitors (Fig. 2d and Supplementary Fig. 21). For example, upon performing consecutive pNPP injections, we observed a decrease in spike intensity and an increase in reaction time, consistent with accumulation of the product, inorganic phosphate (P_i), a competitive inhibitor of this enzyme. We show that by fitting a single fluorescence spike using Michaelis–Menten differential equations with competitive product inhibition⁵¹, one can extract the K_M , the catalytic rate constant (k_{cat}) and, from these, the catalytic efficiency (k_{cat}/K_M) (Fig. 2e). Indeed, we determined K_M ($5.0 \pm 0.1 \mu\text{M}$), k_{cat} ($32.1 \pm 0.9 \text{ s}^{-1}$) and k_{cat}/K_M ($6.4 \pm 0.3 \text{ M}^{-1} \text{ s}^{-1}$) values similar to those reported in the literature⁵² (Supplementary Table 1). Notably, the K_M values determined by plotting spike intensity and by fitting a single spike were also




Fig. 6 | Rapid screening strategy for identification of functional nanoantennas for protein G binding IgG. **a,b**, Plate reader screening strategy (**a**) to rapidly identify a nanoantenna that reports the binding of goat IgG to biotinylated protein G (bPG) (**b**) using the nanoantenna-SA platform. **c**, Results obtained for rapid screening of 12 nanoantennas for the aforementioned system. **d,e**, Cuvette validation (**d**) of results for nanoantennas 1, 6 and 10 displays similar trends to the plate reader format. Also shown is the semirationally selected longer FAM L41 PEG (**e**). **f**, The nanoantenna-SA-bPG complex detects goat IgG and SARS-CoV-2 IgG/IgM while remaining silent to a sample without SARS-CoV-2 IgG/IgM and to the enzyme AP. As an additional control, replacing bPG with biotinylated protein A (bPA), which does not bind goat IgG, does not display a signal change. Ab, antibody. In **c,f**, all experiments were performed with $n=1$ biologically independent protein and antibody samples examined over three independent experiments. Data are presented as mean values \pm s.e.m.

consistent. Crucially, similar values were also obtained by monitoring pNP product generation using UV-visible spectroscopy, supporting that neither the nanoantenna nor SA affect the kinetic parameters of the enzyme (Supplementary Figs. 22–24 and Supplementary Table 1). Next, using a similar fitting procedure⁵¹, we modeled the eight spikes from the same enzyme sample and determined the inhibition constant (K_i), a measure of the inhibitory effect of the P_i product (Fig. 2f; see Supplementary Fig. 25a–d for complete fitting example). This K_i ($48.4 \pm 2.0 \mu\text{M}$) was close to the previously reported values (Supplementary Table 2)^{48,52}. Moreover, the decrease in spike intensities was consistent with the expected decrease in the reaction rate due to inhibition (Supplementary Fig. 25e).

Fluorescent nanoantennas can be used to monitor the AP-mediated hydrolysis of any substrate, including biomolecules. Indeed, all of the chemically diverse substrates tested herein exhibited a similar fluorescence spike during hydrolysis: pNPP, 4-methylumbelliferylphosphate (4MUP), pyrophosphate

(PP_i)²⁹, β -glycerophosphate (BGP), phosphoenolpyruvate (PEP), L-phosphoserine (PSer), pyridoxal 5'-phosphate (PLP)²⁹, D-glucose-6-phosphate (G6P), D-fructose-6-phosphate (F6P), adenosine 5'-monophosphate (AMP), adenosine 5'-diphosphate (ADP), adenosine 5'-triphosphate (ATP)¹⁹, guanosine 5'-triphosphate (GTP)^{18,19}, phosphocreatine (PCr) and amifostine²⁰ (Fig. 3). Using the 'one-shot' fitting strategy described above, each substrate displayed K_M and k_{cat} values consistent with previously reported values, when available, while others were characterized with calf intestinal AP for the first time (Fig. 3 and Supplementary Table 3). Furthermore, with 4MUP, which generates fluorescent 4-methylumbelliferone (4MU; also called hycromone), we found that a single fluorescence spike provided K_M and k_{cat} values that agreed with those determined by the traditional product generation method (Extended Data Fig. 9). Simply fitting one 4MU product progress curve, however, provided markedly overestimated values^{66,67}. In addition to the biomolecular substrates, we also tested amifostine, a prodrug used to protect normal cells during

chemotherapy and radiotherapy, which is putatively hydrolyzed to its active metabolite form by intestinal AP^{20,21}. While the K_M of amifostine was comparable to that of the other tested substrates, its k_{cat} was the slowest, likely due to AP not having evolved to process its P–S bond, unlike for the P–O and P–N bonds of biomolecular substrates. Fluorescent nanoantennas also enabled real-time monitoring of the hydrolysis of ~10-kDa lipopolysaccharides (LPS) (Supplementary Fig. 27)^{17,31}. Deriving kinetic parameters for LPS, however, remains challenging due to uncertain sample concentration and the number of phosphates hydrolyzed per LPS molecule⁶⁸.

Fluorescent nanoantennas can also be used to screen for non-product inhibitors and activators by monitoring their effect on the AP-mediated hydrolysis of a substrate. For example, we characterized the K_i of five oxyanion inhibitors, as well as the effect of Mg^{2+} , on the hydrolysis of amifostine by AP (Fig. 4 and Supplementary Table 4). The kinetic profiles of phosphate and vanadate agree with the theoretical result for relatively weak and strong competitive inhibitors, respectively (Extended Data Fig. 10).

Characterizing protein conformational states. Other known conformational states of AP can be detected with fluorescent nanoantennas (Fig. 5a). Vanadate (V_i ; following the same naming format as for P_i), for example, is a putative transition state analog (TSA) inhibitor of AP, meaning that it stabilizes a geometry of the enzyme that is reminiscent of the transition state³⁴. Nanoantennas detect V_i binding to bAP via fluorescence quenching (Fig. 5b,c; see control in Supplementary Fig. 30). This quenching response contrasts with the increase in fluorescence observed upon substrate binding to the same site, further indicating that the nanoantennas can efficiently distinguish between highly similar conformational states. Interestingly, tungstate (W_i), also recently proposed as a TSA inhibitor of AP³⁵, seems to induce a distinct conformational change as evidenced by the increase in fluorescence (Fig. 5c). In contrast, P_i and molybdate (Mo_i), which likewise bind at the active site, did not induce a conformational change detectable by the nanoantennas (Fig. 5c). As determined by fluorescence change, the observed dissociation constants (K_D) of vanadate ($0.54 \pm 0.01 \mu M$) and tungstate ($7.6 \pm 0.2 \mu M$) are consistent with their K_i determined using the ‘one-shot’ fitting of the fluorescent spike ($1.2 \pm 0.3 \mu M$ and $10.1 \pm 3.5 \mu M$, respectively; Fig. 4 and Supplementary Table 4), and with the literature⁶⁹.

Nanoantennas can also monitor large conformational changes, such as protein unfolding by thermal denaturation. When attached to SA, nanoantennas display a distinct transition at a melting temperature (T_M) of $91.7^\circ C \pm 0.7^\circ C$ (Fig. 5d,e). This likely represents dissociation of FAM from SA, rather than unfolding of SA or detachment of the whole nanoantenna, since the nanoantenna-SA platform remained stable over this temperature range (Supplementary Fig. 31). With bound bAP, the nanoantennas exhibit a distinct transition at a T_M of $66.4^\circ C \pm 0.1^\circ C$ (Fig. 5d,e), consistent with the unfolding temperature of AP (Supplementary Figs. 31 and 32)³⁷. One potential application of T_M determination by fluorescent nanoantennas could be the characterization of a specific protein in the presence of others (Supplementary Fig. 33). The nanoantennas further enabled derivation of the apparent Gibbs free energy (ΔG) for the thermal unfolding of bAP ($\Delta G = -7.8 \pm 0.5 \text{ kcal mol}^{-1}$ at $T = 37^\circ C$; Supplementary Fig. 34).

Rapid screening of nanoantennas. We explored the potential universality of the nanoantenna strategy by using a different model protein that involves protein–protein interaction. As a proof-of-concept, we employed Protein G from streptococcal bacteria, which binds goat immunoglobulin G (IgG) with high affinity⁵⁴. To facilitate nanoantenna selection, we designed a 96-well-plate screening assay that leverages the convenience of the nanoantenna-SA platform (Fig. 6a,b and Supplementary Note 2). This enabled us to rapidly test 12 nanoantennas with different linker lengths, linker types, chemical

connections and fluorophores. We first prepared the plate by adding the different nanoantennas, followed by the addition of SA. We then added biotinylated Protein G (bPG) and recorded the fluorescence intensity in all wells. Upon addition of goat IgG, we observed that nanoantenna 6 (5′ T 6-FAM L21 PEG) displayed the largest fluorescence quenching, while nanoantenna 10 (3′ Cy3 L12 ssDNA) displayed the largest fluorescence enhancement (Fig. 6c). After identifying these candidate nanoantennas, we confirmed their performance in cuvettes (Fig. 6d,e). This screening strategy also offers an opportunity to further optimize performance via semirational design of the fluorescent nanoantenna. For example, we observed that for this particular protein function, the flexible L21 PEG nanoantenna enabled the best sensitivity for the T 6-FAM fluorophore (Fig. 6c). Although the ssDNA nanoantennas with T 6-FAM were not as sensitive in comparison, we noticed that the longer ones were better than the shorter ones (Fig. 6c). Therefore, we subsequently tested a longer PEG nanoantenna (5′ T 6-FAM L41 PEG), not included in our initial screening, and found that it did indeed display improved sensitivity to goat IgG binding (Fig. 6e). Ultimately, however, we selected the Cy3 nanoantenna for subsequent investigations due to its signal-on fluorescence change (Fig. 6e).

In principle, this nanoantenna-SA-bPG complex could be used as a signal-on biosensor to detect the presence of specific types of antibodies (Fig. 6f; bPG + IgG)⁵⁴. Indeed, a sample containing SARS-CoV-2 IgG/IgM led to a similar fluorescence increase (Fig. 6f; bPG + CoV antibody), while it did not respond to a sample negative for SARS-CoV-2 IgG/IgM (Fig. 6f; bPG + Ctrl) nor to the enzyme AP (nonbiotinylated) (Fig. 6f; bPG + AP). Furthermore, swapping bPG for biotinylated Protein A (bPA), which does not bind goat IgG⁵⁴, also did not display a signal increase (Fig. 6f; bPA + IgG; Supplementary Fig. 35). This control with bPA further shows that the target goat IgG does not nonspecifically interact with the nanoantenna-SA platform. Overall, these results indicate that fluorescent nanoantennas can be rapidly screened for their ability to monitor distinct protein functions.

Discussion

Here, we have introduced the use of fluorescent nanoantennas as a strategy to monitor protein dynamics. A platform and linker mediate dye-protein interactions via a high local concentration. Protein conformational changes affecting the dye’s chemical environment generate a change in the fluorescence signal. By tuning linker length and dye, we have leveraged this strategy to monitor the functions of three proteins: streptavidin, alkaline phosphatase and Protein G. Several observations supported our proposed signaling mechanism. First, FAM nanoantennas detected all conformational changes in their surroundings: their binding to SA, subsequent binding of biotin or a biotinylated protein to SA, and the function of that protein. Most interestingly, the nanoantenna also detected five distinct conformational states of AP: its ground state, enzyme–substrate complexes with various substrates, the distinct conformational changes induced by vanadate³⁴ and tungstate³⁵ binding, and its unfolded state. Second, 16 structurally distinct substrates of AP, all hydrolyzed by the same mechanism³³, exhibited similar fluorescence signatures. This fluorescence signature enabled easy characterization of Michaelis–Menten kinetic parameters of all tested substrates and inhibitors. Third, nanoantennas employing chemically diverse dyes that bind to different locations on AP differed in sensitivity but displayed the same kinetics during substrate hydrolysis. Fourth, the strategy was not limited to a single fluorescent dye, since FAM nanoantennas were optimal for monitoring bAP function while the Cy3 nanoantenna was best for bPG. Finally, MD simulations also suggested a signaling mechanism based on conformational change.

A main advantage of fluorescent nanoantennas is their convenience. For example, the nanoantennas can be used with accessible and straightforward fluorescence spectroscopy, as opposed to

specialized techniques. Furthermore, various conjugation strategies can be developed to facilitate nanoantenna-protein preparation. For instance, here we developed and exploited the modular biotin-SA platform. This requires only nonspecific biotinylation of the protein of interest, as opposed to site-specific attachment chemistry of fluorophores. Indeed, lysine residues can be nonspecifically biotinylated with a simple commercially available kit. While it cannot be assumed to be necessarily true in all cases, biotinylation often does not affect protein function⁵⁷. In comparison, the more complex site-specific labeling needed for FRET strategies has been found to perturb the function of β -lactamases³ and dihydrofolate reductase⁷⁰. In the case where biotinylation would affect a protein's function, other modular attachment strategies could also be developed; for example, one could envisage the use of N or C terminus affinity tags⁷¹. When employing a modular attachment strategy, efficient nanoantennas can also be rapidly screened using a 96-well plate, as we demonstrated with bPG.

Another important advantage of fluorescent nanoantennas is their versatility. Nanoantennas can be used to monitor distinct biomolecular mechanisms in real time, including small and large conformational changes—in principle, any event that can affect the dye's fluorescence emission. Furthermore, since nanoantennas can distinguish between unbound and substrate-bound enzyme conformations, they can supplant nonnatural colorimetric⁴² and fluorogenic^{43,44} substrates, as well as laborious assays for spectroscopically silent substrates⁴⁷. For example, nanoantennas enable real-time, 'one-shot' kinetic characterization of any substrate, such as ATP and amifostine^{18–21,29}. In contrast, standard methods to determine K_M and k_{cat} for spectroscopically silent substrates require approximately ten measurements at different substrate concentrations^{47,72}. They also compare favorably with other 'one-shot' strategies that require microfluidics to generate a range of substrate concentrations, in addition to a fluorescent product⁷³. Nanoantennas, however, do have some limitations. For example, unlike other noteworthy techniques^{7,8,63,64,74–77}, nanoantennas cannot quantify specific distance variations. Also, not all dye-protein combinations generate a signal change during protein function; some proteins might not work with any dyes. However, looking to the future, we believe that the universality of the nanoantenna strategy may be improved by screening a larger library of dyes and by further exploring the predictive potential of docking and MD simulations. We anticipate that our fluorescent nanoantennas will find exciting applications in the study of protein structure and function and in high-throughput screening.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41592-021-01355-5>.

Received: 26 February 2021; Accepted: 10 November 2021;
Published online: 30 December 2021

References

- Hammes-Schiffer, S. & Klinman, J. Emerging concepts about the role of protein motion in enzyme catalysis. *Acc. Chem. Res.* **48**, 899–899 (2015).
- Lobb, R. R. & Auld, D. S. Determination of enzyme mechanisms by radiationless energy transfer kinetics. *Proc. Natl Acad. Sci. USA* **76**, 2684–2688 (1979).
- Au, H.-W., Tsang, M.-W., So, P.-K., Wong, K.-Y. & Leung, Y.-C. Thermostable β -lactamase mutant with its active site conjugated with fluorescein for efficient β -lactam antibiotic detection. *ACS Omega* **4**, 20493–20502 (2019).
- Vallée-Bélisle, A. & Michnick, S. W. Visualizing transient protein-folding intermediates by tryptophan-scanning mutagenesis. *Nat. Struct. Mol. Biol.* **19**, 731–736 (2012).
- Gregorio, G. G. et al. Single-molecule analysis of ligand efficacy in β_2 AR–G-protein activation. *Nature* **547**, 68–73 (2017).
- Comstock, M. J. et al. Direct observation of structure-function relationship in a nucleic acid-processing enzyme. *Science* **348**, 352–354 (2015).
- Hwang, H. & Myong, S. Protein induced fluorescence enhancement (PIFE) for probing protein–nucleic acid interactions. *Chem. Soc. Rev.* **43**, 1221–1229 (2014).
- Lerner, E. et al. Toward dynamic structural biology: two decades of single-molecule Förster resonance energy transfer. *Science* **359**, eaan1133 (2018).
- Chen, Y., Tsao, K. & Keillor, J. W. Fluorogenic protein labelling: a review of photophysical quench mechanisms and principles of fluorogen design. *Can. J. Chem.* **93**, 389–398 (2015).
- Unnikrishnan, B., Wu, R.-S., Wei, S.-C., Huang, C.-C. & Chang, H.-T. Fluorescent carbon dots for selective labeling of subcellular organelles. *ACS Omega* **5**, 11248–11261 (2020).
- Eisenmesser, E. Z., Bosco, D. A., Akke, M. & Kern, D. Enzyme dynamics during catalysis. *Science* **295**, 1520–1523 (2002).
- Ma, X., Hortelão, A. C., Patiño, T. & Sánchez, S. Enzyme catalysis to power micro/nanomachines. *ACS Nano* **10**, 9111–9122 (2016).
- Abou-Zied, O. K. & Sulaiman, S. A. J. Site-specific recognition of fluorescein by human serum albumin: a steady-state and time-resolved spectroscopic study. *Dyes Pigment.* **110**, 89–96 (2014).
- Pisoni, D. S. et al. Symmetrical and asymmetrical cyanine dyes. Synthesis, spectral properties, and BSA association study. *J. Org. Chem.* **79**, 5511–5520 (2014).
- Millán, J.L. *Mammalian Alkaline Phosphatases: From Biology to Applications in Medicine and Biotechnology* (John Wiley & Sons, 2006).
- Lallès, J.-P. Recent advances in intestinal alkaline phosphatase, inflammation, and nutrition. *Nutr. Rev.* **77**, 710–724 (2019).
- Bates, J. M., Akerlund, J., Mittge, E. & Guillemin, K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. *Cell Host Microbe* **2**, 371–382 (2007).
- Malo, M. S. et al. Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. *Am. J. Physiol. Gastrointest. Liver Physiol.* **306**, G826–G838 (2014).
- Mizumori, M. et al. Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum. *J. Physiol.* **587**, 3651–3663 (2009).
- Giatromanolaki, A., Sivridis, E., Maltezos, E. & Koukourakis, M. I. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. *Semin. Oncol.* **29**, 14–21 (2002).
- Hofer, M. et al. Two new faces of amifostine: protector from DNA damage in normal cells and inhibitor of DNA repair in cancer cells. *J. Med. Chem.* **59**, 3003–3017 (2016).
- Riedel, C. et al. The heat released during catalytic turnover enhances the diffusion of an enzyme. *Nature* **517**, 227–230 (2015).
- Tsai, L.-C. et al. Expression and regulation of alkaline phosphatases in human breast cancer MCF-7 cells. *Eur. J. Biochem.* **267**, 1330–1339 (2000).
- Rao, S. R. et al. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. *Br. J. Cancer* **116**, 227–236 (2017).
- Hung, H.-Y. et al. Preoperative alkaline phosphatase elevation was associated with poor survival in colorectal cancer patients. *Int. J. Colorectal Dis.* **32**, 1775–1778 (2017).
- Namikawa, T. et al. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer. *Gastric Cancer* **22**, 684–691 (2019).
- Kaliannan, K. et al. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. *Proc. Natl Acad. Sci. USA* **110**, 7003–7008 (2013).
- José, L. M. & Michael, P. W. Alkaline Phosphatase and Hypophosphatasia. *Calcif. Tissue Int.* **98**, 398–416 (2016).
- Waymire, K. G. et al. Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. *Nat. Genet.* **11**, 45–51 (1995).
- Park, J.-B. et al. Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent. *Eur. Heart J.* **34**, 920–931 (2012).
- Yang, W. H. et al. Recurrent infection progressively disables host protection against intestinal inflammation. *Science* **358**, eaao5610 (2017).
- To, K. K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect. Dis.* **20**, 565–574 (2020).
- Stec, B., Holtz, K. M. & Kantrowitz, E. R. A revised mechanism for the alkaline phosphatase reaction involving three metal ions. *J. Mol. Biol.* **299**, 1303–1311 (2000).
- Holtz, K. M., Stec, B. & Kantrowitz, E. R. A model of the transition state in the alkaline phosphatase reaction. *J. Biol. Chem.* **274**, 8351–8354 (1999).

35. Peck, A., Sunden, F., Andrews, L. D., Pande, V. S. & Herschlag, D. Tungstate as a transition state analog for catalysis by alkaline phosphatase. *J. Mol. Biol.* **428**, 2758–2768 (2016).
36. Roston, D., Demapan, D. & Cui, Q. Leaving group ability observably affects transition state structure in a single enzyme active site. *J. Am. Chem. Soc.* **138**, 7386–7394 (2016).
37. Bortolato, M., Besson, F. & Roux, B. Role of metal ions on the secondary and quaternary structure of alkaline phosphatase from bovine intestinal mucosa. *Proteins* **37**, 310–318 (1999).
38. Ásgeirsson, B., Markússon, S., Hlynisdóttir, S. S., Helland, R. & Hjörleifsson, J. G. X-ray crystal structure of *Vibrio* alkaline phosphatase with the non-competitive inhibitor cyclohexylamine. *Biochem. Biophys. Rep.* **24**, 100830 (2020).
39. Aziz, H. et al. Synthesis, characterization, in vitro tissue-nonspecific alkaline phosphatase (TNAP) and intestinal alkaline phosphatase (IAP) inhibition studies and computational evaluation of novel thiazole derivatives. *Bioorg. Chem.* **102**, 104088 (2020).
40. Kiffer-Moreira, T. et al. Catalytic signature of a heat-stable, chimeric human alkaline phosphatase with therapeutic potential. *PLoS ONE* **9**, e89374 (2014).
41. Jiang, Y., Li, X. & Walt, D. R. Single-molecule analysis determines isozymes of human alkaline phosphatase in serum. *Angew. Chem. Int. Ed. Engl.* **59**, 18010–18015 (2020).
42. Bessey, O. A., Lowry, O. H. & Brock, M. J. A method for the rapid determination of alkaline phosphatase with five cubic millimeters of serum. *J. Biol. Chem.* **164**, 321–329 (1946).
43. Fernley, H. & Walker, P. Kinetic behaviour of calf-intestinal alkaline phosphatase with 4-methylumbelliferyl phosphate. *Biochem. J.* **97**, 95–103 (1965).
44. Deng, J., Yu, P., Wang, Y. & Mao, L. Real-time ratiometric fluorescent assay for alkaline phosphatase activity with stimulus responsive infinite coordination polymer nanoparticles. *Anal. Chem.* **87**, 3080–3086 (2015).
45. Sanzhaeva, U. et al. Imaging of enzyme activity by electron paramagnetic resonance: concept and experiment using a paramagnetic substrate of alkaline phosphatase. *Angew. Chem. Int. Ed. Engl.* **57**, 11701–11705 (2018).
46. Gyurcsányi, R. E., Bereczki, A., Nagy, G., Neuman, M. R. & Lindner, E. Amperometric microcells for alkaline phosphatase assay. *Analyst* **127**, 235–240 (2002).
47. Baykov, A. A., Evtushenko, O. A. & Aვაeva, S. M. A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. *Anal. Biochem.* **171**, 266–270 (1988).
48. Liu, Y. & Schanze, K. S. Conjugated polyelectrolyte-based real-time fluorescence assay for alkaline phosphatase with pyrophosphate as substrate. *Anal. Chem.* **80**, 8605–8612 (2008).
49. Liu, Y. et al. Selective sensing of phosphorylated peptides and monitoring kinase and phosphatase activity with a supramolecular tandem assay. *J. Am. Chem. Soc.* **140**, 13869–13877 (2018).
50. Wang, Y., Wang, G., Moitessier, N. & Mittermaier, A. K. Enzyme kinetics by isothermal titration calorimetry: allostery, inhibition, and dynamics. *Front. Mol. Biosci.* **7**, 583826 (2020).
51. Di Trani, J. M., Moitessier, N. & Mittermaier, A. K. Complete kinetic characterization of enzyme inhibition in a single isothermal titration calorimetric experiment. *Anal. Chem.* **90**, 8430–8435 (2018).
52. Honarmand Ebrahimi, K., Hagedoorn, P.-L., Jacobs, D. & Hagen, W. R. Accurate label-free reaction kinetics determination using initial rate heat measurements. *Sci. Rep.* **5**, 16380 (2015).
53. Zhang, L., Buchet, R. & Azzar, G. Phosphate binding in the active site of alkaline phosphatase and the interactions of 2-nitrosoacetophenone with alkaline phosphatase-induced small structural changes. *Biophys. J.* **86**, 3873–3881 (2004).
54. Akerström, B., Brodin, T., Reis, K. & Björck, L. Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies. *J. Immunol.* **135**, 2589–2592 (1985).
55. Kada, G., Falk, H. & Gruber, H. J. Accurate measurement of avidin and streptavidin in crude biofluids with a new, optimized biotin–fluorescein conjugate. *Biochim. Biophys. Acta* **1427**, 33–43 (1999).
56. Buranda, T. et al. Ligand receptor dynamics at streptavidin-coated particle surfaces: a flow cytometric and spectrofluorimetric study. *J. Phys. Chem. B* **103**, 3399–3410 (1999).
57. Iyer, A., Chandra, A. & Swaminathan, R. Hydrolytic enzymes conjugated to quantum dots mostly retain whole catalytic activity. *Biochim. Biophys. Acta Gen. Subj.* **1840**, 2935–2943 (2014).
58. Fairhead, M., Krndija, D., Lowe, E. D. & Howarth, M. Plug-and-play pairing via defined divalent streptavidins. *J. Mol. Biol.* **426**, 199–214 (2014).
59. Neish, C. S., Martin, I. L., Henderson, R. M. & Edwardson, J. M. Direct visualization of ligand-protein interactions using atomic force microscopy. *Br. J. Pharmacol.* **135**, 1943–1950 (2002).
60. Deetanya, P. et al. Interaction of 8-anilino-naphthalene-1-sulfonate with SARS-CoV-2 main protease and its application as a fluorescent probe for inhibitor identification. *Comput. Struct. Biotechnol. J.* **19**, 3364–3371 (2021).
61. Chen, H., Ahsan, S. S., Santiago-Berrios, M. E. B., Abuña, H. D. & Webb, W. W. Mechanisms of quenching of Alexa fluorophores by natural amino acids. *J. Am. Chem. Soc.* **132**, 7244–7245 (2010).
62. Togashi, D. M., Szczupak, B., Ryder, A. G., Calvet, A. & O’Loughlin, M. Investigating tryptophan quenching of fluorescein fluorescence under protolytic equilibrium. *J. Phys. Chem. A* **113**, 2757–2767 (2009).
63. Nguyen, B., Ciuba, M. A., Kozlov, A. G., Levitus, M. & Lohman, T. M. Protein environment and DNA orientation affect protein-induced Cy3 fluorescence enhancement. *Biophys. J.* **117**, 66–73 (2019).
64. Rashid, F. et al. Initial state of DNA-Dye complex sets the stage for protein induced fluorescence modulation. *Nat. Commun.* **10**, 2104 (2019).
65. Marras, S. A. E., Kramer, F. R. & Tyagi, S. Efficiencies of fluorescence resonance energy transfer and contact-mediated quenching in oligonucleotide probes. *Nucleic Acids Res.* **30**, e122 (2002).
66. Zimmerle, C. T. & Frieden, C. Analysis of progress curves by simulations generated by numerical integration. *Biochem. J.* **258**, 381–387 (1989).
67. Palmier, M. O. & Van Doren, S. R. Rapid determination of enzyme kinetics from fluorescence: overcoming the inner filter effect. *Anal. Biochem.* **371**, 43–51 (2007).
68. Komazin, G. et al. Substrate structure-activity relationship reveals a limited lipopolysaccharide chemotype range for intestinal alkaline phosphatase. *J. Biol. Chem.* **294**, 19405–19423 (2019).
69. Ziegler, A. J., Florian, J., Ballicora, M. A. & Herlinger, A. W. Alkaline phosphatase inhibition by vanadyl- β -diketone complexes: electron density effects. *J. Enzym. Inhib. Med. Chem.* **24**, 22–28 (2009).
70. Chen, S. et al. Detection of dihydrofolate reductase conformational change by FRET using two fluorescent amino acids. *J. Am. Chem. Soc.* **135**, 12924–12927 (2013).
71. Schwaminger, S. P. et al. Immobilization of PETase enzymes on magnetic iron oxide nanoparticles for the decomposition of microplastic PET. *Nanoscale Adv.* **3**, 4395–4399 (2021).
72. Ritchie, R. J. & Prvan, T. A simulation study on designing experiments to measure the K_m of Michaelis–Menten kinetics curves. *J. Theor. Biol.* **178**, 239–254 (1996).
73. Mao, H., Yang, T. & Cremer, P. S. Design and characterization of immobilized enzymes in microfluidic systems. *Anal. Chem.* **74**, 379–385 (2002).
74. Gordon, S. E., Munari, M. & Zagotta, W. N. Visualizing conformational dynamics of proteins in solution and at the cell membrane. *eLife* **7**, e37248 (2018).
75. Pantazis, A., Westerberg, K., Althoff, T., Abramson, J. & Olcese, R. Harnessing photoinduced electron transfer to optically determine protein sub-nanoscale atomic distances. *Nat. Commun.* **9**, 4738 (2018).
76. Jarecki, Brian W. et al. Tethered spectroscopic probes estimate dynamic distances with subnanometer resolution in voltage-dependent potassium channels. *Biophys. J.* **105**, 2724–2732 (2013).
77. Mansoor, S. E., DeWitt, M. A. & Farrens, D. L. Distance mapping in proteins using fluorescence spectroscopy: the tryptophan-induced quenching (TrIQ) method. *Biochemistry* **49**, 9722–9731 (2010).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2021

Methods

Enzymes, substrates and other materials. AP used in this study was from calf intestinal mucosa. Unconjugated AP, bAP, streptavidin-conjugated AP (SA-AP), bPG, bPA and goat IgG (whole molecule) were purchased from Rockland Immunochemicals. SA was from New England Biolabs. VIROTROL SARS-CoV-2 (reactive for SARS-CoV-2 total IgG/IgM and IgG antibodies) and VIROCLEAR SARS-CoV-2 (nonreactive for SARS-CoV-2 total IgG/IgM and IgG antibodies) were from Bio-Rad Laboratories. See Supplementary Information for enzyme storage buffer conditions, as well as details about substrates, inhibitors and other reagents.

Oligonucleotide synthesis. Labeled and unlabeled oligonucleotides were made by standard phosphoramidite chemistry with a solid support DNA/RNA H-6 Synthesizer from K&A Laborgeräte. Purification of strands with a 5' protecting group (4,4'-dimethoxytrityl (DMT)) was performed with a P-8 oligonucleotide purifier. Strands without a protecting group (for example, 6-FAM and 5-FAM) were purified using high performance liquid chromatography (HPLC) with a 1260 Infinity HPLC instrument from Agilent. The mobile phase was 0.1 M triethylamine with increasing concentration of acetonitrile, and the stationary phase was an XBridge Oligonucleotide BEH C18 OBD Prep Column, 130 Å, 2.5 µm, 10 mm × 50 mm from Waters Corporation. Extinction coefficients at 260 nm were predicted using the OligoAnalyzer website (<https://www.idtdna.com/calc/analyzer>) from Integrated DNA Technologies. DNA was then quantified by UV-visible spectroscopy with a Cary 60 from Agilent or a NanoDrop 2000c Spectrophotometer from Thermo Fisher Scientific. Oligonucleotides were prepared as 200 µl, ~800 µM stock solutions, and used as 1 ml, 100 µM intermediate solutions; all stored at -20 °C.

Fluorescence. Fluorescence spectroscopy was recorded with a Cary Eclipse Fluorescence Spectrophotometer from Agilent. For measurements in quartz cuvettes, it was equipped with a Peltier Thermostatted Multicell Holder Accessory from Agilent. For the plate reader measurements, it was equipped with a Microplate Reader ACCY from Varian and used Nunc MaxiSorp 350 µl Black 96-well plates from Thermo Fisher Scientific. Fluorescence spectra were recorded with Scan software, fluorescence kinetics with Kinetics software and melting temperatures with Thermal software (Agilent). Typical settings were: excitation (ex)/emission (em) slit widths 5 nm, excitation 498 nm and emission 520 nm for FAM (wavelengths denoted hereafter in the format 498/520), CAL 540/561, carboxyrhodamine (ROX) 575/602, carboxytetramethylrhodamine (TAMRA) 565/580, Cyanine 3 (Cy3) 546/563, Quasar 570 (Q570) 550/570, Quasar 670 (Q670) 644/670, Pulsar 650 (P650) 460/650 and methylene blue (MB) 670/690. The photomultiplier tube detector voltage was typically 635 V for 150 nM fluorescent nanoantennas, but 800 V for those with MB or P650, as well as 800 V for experiments with 15 nM FAM nanoantennas. For plate reader measurements, it was 600 V. For kinetics, we typically used averaging time 3.0 s, cycle 0.04 min. For spectra, we typically used CAT mode with 10 scans at 'medium' speed (scan rate 600 nm min⁻¹, averaging time 0.1 s, data interval 1 nm).

A typical study of nanoantenna fluorescence emission over time (for example, Fig. 1a) was as follows. The intermediate nanoantenna stock solution was added to buffer in a quartz cuvette (150 nM), followed by waiting 5–10 min for the fluorescence signal to equilibrate. After observing a stable signal, we performed subsequent additions of complementary DNA, proteins, substrates, etc. Final volume at addition of substrate was 1 ml. We typically mixed by rapidly pipetting ~10× using ~50 µl volume while being careful not to pipette bubbles into the solution. A waiting time of 3–10 min for each step was taken to ensure binding and equilibration. In most cases, cDNA and SA bound very quickly (several seconds), but biotinylated proteins took longer (sometimes up to several minutes). In a typical experiment, we added SA (50 nM) and then bAP (100 nM) for a nanoantenna:SA:bAP ratio of 3:1:2. For some faster lots of enzyme, we added less enzyme, as indicated. Last, we added the substrate (for example, pNPP). To make the effects of dilution negligible, most additions were aliquots of several µl.

For dual absorbance and fluorescence kinetics of the same sample, we used a SX20 Stopped Flow Spectrometer from Applied Photophysics with Pro-Data SX software and with a 495-nm cut-off filter. Nanoantenna-protein complex was prepared in one syringe and substrate in another syringe, which were then mixed during the measurement.

Buffer conditions. In our initial studies of the nanoantenna concept with AP and of various dyes (Fig. 1), buffer conditions were 200 mM Tris, 300 mM NaCl, 1 mM MgCl₂, pH 7.0 and 37 °C, with 100 nM commercially available bAP and 50 nM SA. A ratio of three nanoantennas per SA, for example, used 150 nM nanoantennas. Later, for comparison with another recent study (Fig. 2)⁵², buffer conditions were 100 mM Tris, 10 mM NaCl, pH 8.0 and 30 °C, with either 100 nM bAP (Fig. 2a–c) or 10 nM bAP (Fig. 2d,e; nanoantennas and SA were adjusted proportionally). For characterization of substrates (Fig. 3), the same buffer was used but at 37 °C with 150 nM nanoantennas, 50 nM SA, commercially available 20 nM bAP and 300 µM substrate. Less bAP was used because this lot of bAP enzyme displayed faster substrate hydrolysis kinetics than previous lots that we had purchased. Note that we did observe some enzyme batch-to-batch variation (Supplementary Fig. 26), but the results were still in good agreement with the range of literature values for pNPP. See Supplementary Table 3 for complete kinetic parameters, and Supplementary Figs. 28 and 29 for a discussion of fluorescence baseline. For characterization of effectors (Fig. 4), the conditions were the same as in Fig. 3, with either 30 µM inhibitor or 5 mM

Mg²⁺. For vanadate and related experiments (Fig. 5b,c), the same conditions were also used but with 100 nM of commercially available bAP. In experiments for thermal denaturation of AP (Fig. 5d,e), to reduce pH variation with temperature, we changed the buffer conditions to 100 mM NaCl, 50 mM Na₂HPO₄, pH 7.0, 37 °C and used 100 nM of commercially available bAP. For experiments with Protein G in the 96-well plate (Fig. 6c), buffer conditions were 200 mM Tris, 300 mM NaCl, pH 7.0, room temperature, with 500 nM nanoantennas, 167 nM SA, 167 nM bPG and ~1,000 nM goat IgG. For subsequent experiments with Protein G in cuvettes (Fig. 6e,f), the same buffer was used at 37 °C with 150 nM nanoantennas, 50 nM SA, 50 nM bPG or bPA and ~500 nM goat IgG, 20 µL SARS-CoV-2 antibodies or control (Ctrl) (unknown concentration) or 500 nM AP. Dilution of antibodies was 7.5 µl goat IgG in 292.5 µl (well plate) or 992.5 µl (cuvettes) of buffer, and 20 µl VIROTROL SARS-CoV-2 in 980 µl (cuvettes) of buffer. Supplementary figures typically used the same conditions as associated experiments in the main text, but see also their captions.

Software. Data analysis was performed in KaleidaGraph from Synergy Software, OriginPro v.9.0 from OriginLab and Microsoft Excel, with all data plotted in KaleidaGraph. The log *D* calculations, as a measure of hydrophobicity, were done by MarvinSketch software from ChemAxon. Molecular structure images were also generated with MarvinSketch. Density functional theory (DFT) computations to estimate PEG-based nanoantenna length were done via ChemCompute (<https://chemcompute.org>)⁷⁸.

Molecular docking simulations. Docking was performed on the SwissDock web server (<http://www.swissdock.ch>)^{79,80} from the Swiss Institute of Bioinformatics. The 'target' protein structure for streptavidin was PDB 6M9B (*Streptomyces avidinii*)⁸¹. Since there was no crystal structure available for the AP used in this study, we instead built a homology model on the SWISS-MODEL web server (<https://swissmodel.expasy.org>) from the sequence of P19111 (*Bos taurus* intestinal alkaline phosphatase) and the structure of 1ZEF (*Homo sapiens* placental alkaline phosphatase) as the template^{82–84}. The global model quality estimation was 0.79, the quaternary structure quality estimate was 0.93 and the identity was 75.52. 'Ligand' structures (for example, biotin, pNPP, dyes, etc.) were determined to be the major microspecies at pH 7.0 using MarvinSketch software, the manufacturer's product description and available literature (further details in Supplementary Fig. 13), followed by optimization in Avogadro software⁸⁵. Analysis of the docking simulation was done in UCSF Chimera software using the View Dock tool (Type Selection: Dock 4, 5 or 6)⁸⁶. Note that dyes in the simulation did not include the attachment chemistry to the DNA, nor the DNA itself, and are accordingly an estimation of the binding site. Docking simulations were replicated ten times to confirm reproducibility (or lack thereof) for the binding site.

MD simulations. Structure preparation. All protein ligand complexes were prepared using the AP homology model. Two sets of complexes were generated for all three fluorophores (FAM, CAL and Cy3) in complex with or without pNPP substrate. From the docking study of FAM, we chose the best pose ('position') that would have the *para* and *ortho* position of the DNA linker attachment point accessible by the solvent. Since AP is a dimer, both binding locations were populated with different ligand conformations for double sampling. In the case of the substrate-bound pNPP/FAM complex, the FAM ligand was redocked to the AP active site with the substrate present. Again, the best scoring pose of the pNPP/FAM ligand complex from the docking run was chosen. The QuickPrep application of MOE2019 software⁸⁷ with default parameters was used to create a fully parameterized all-atomistic model, which was then used to generate the input files for all MD simulations. Separately, the model of the nanoantenna-SA-bAP complex was built using the streptavidin/biotin complex (PDB 6M9B)⁸¹, the AP homology model and the rL12 nanoantenna sequence with 3'-FAM and 5'-T-biotin. The all-atomic model was again generated using the QuickPrep application. A lysine residue in proximity to the AP-binding site was biotinylated and the biotin moiety was placed in the streptavidin active site in a nonclashing conformation. Note that the manufacturer would not disclose the exact composition of the biotin connection to AP (bAP). The DNA linker was constructed using the MOE2019 DNA/RNA builder starting from the crystallized biotin molecule in the neighboring streptavidin active site. Finally, the FAM fluorophore was attached to the 3'-end of the DNA linker and the entire complex energy minimized using the MOE2019 built-in energy minimization application.

MD simulation. The simulation cell and Amber20⁸⁸ input files were generated using MOE2019. The crystallographic water molecules were removed before solvation. Next, the protein/ligand complexes and AP apo structure were embedded in a TIP3P water box with cubic periodic boundary conditions, keeping a distance of 10 Å between the boundaries and the protein. The net charge of the protein was neutralized with 100 mM NaCl. For energy minimization and MD simulations, the Amber14:EHT force field was used and the electrostatic interactions were evaluated by the particle-mesh Ewald method. Each system was energy minimized for 5,000 steps using the Conjugate Gradient method. For equilibration, the system was subjected to a 100-ps simulation to gradually heat the system from 10 K to 300 K. Next, a 100-ps NVT ensemble was generated at 300 K, followed by an NPT ensemble for 200 ps at 300 K and 1 bar. Then, for each complex, a 100-ns production trajectory was generated for further analysis. The trajectory analysis and frame export for the video was done using scripts shared by the CCG support group.

Kinetic fitting (K_M , k_{cat} , K_i). Fitting was performed using MATLAB (v.R2019a) from MathWorks by following a method with a script obtained from the author⁵¹. For the script, see 'Script for fitting kinetic data in MATLAB' in the Supplementary Information. Briefly, Michaelis–Menten differential equations with competitive product inhibition (equations (1)–(5)) were integrated using Euler's method with a time step of $dt=0.1$ s, where K_M is the Michaelis–Menten constant, K_i is the product inhibition constant and k_{cat} is the catalytic rate constant. $[S]_t$, $[P]$, and $[ES]_t$ are the concentration of substrate, product and enzyme–substrate complex at time t , respectively. $Rate_{dil}$ is the rate of dilution of the substrate from the pipette to the cuvette and is estimated to be 2 s during the dilution and 0 otherwise. $[S]_0$ is the initial concentration of substrate in the syringe before dilution. $[E]_0$ is the concentration of enzyme in the cuvette and is assumed to remain constant throughout the course of the kinetics. Note that substrate addition typically dilutes the enzyme by less than 1% and is therefore negligible.

$$\frac{d[P]_t}{dt} = \frac{[E]_0 \times k_{cat} \times [S]_t}{\left(K_M \left(1 + \frac{[P]_t}{K_i}\right) + [S]_t\right)} \quad (1)$$

$$\frac{d[P]_{t+dt}}{dt} = [P]_t + \frac{d[P]_t}{dt} \times dt \quad (2)$$

$$\frac{d[S]_t}{dt} = -\frac{d[P]_t}{dt} + [S]_0 \times Rate_{dil} \quad (3)$$

$$\frac{d[S]_{t+dt}}{dt} = [S]_t + \frac{d[S]_t}{dt} \times dt \quad (4)$$

$$\frac{d[ES]_t}{dt} = \frac{[E]_0 \times [S]_t}{\left(K_M \left(1 + \frac{[P]_t}{K_i}\right) + [S]_t\right)} \quad (5)$$

The fluorescence signal was found to be correlated with the concentration of ES and is fit according to equation (6), where the baseline is the native signal of the nanoantenna-SA-bAP complex, F_{max} is the fluorescence signal of the nanoantenna-SA-bAP complex when all the enzyme is bound with substrate (that is, high substrate concentration) and F_{prod} is the impact of the product concentration on the fluorescence signal of the nanoantenna-SA-bAP complex. Fitting was performed by using the nonlinear least-squares solver lsqcurvefit in MATLAB, which minimizes the sum of the squares of the residuals between the raw data and the computed data. Then, when applicable, the 95% confidence interval of each parameter is calculated using the nlparci function in MATLAB.

$$F_{spike} = \text{Baseline} + F_{max} \times [ES]_t + F_{prod} \times [P]_t \quad (6)$$

Enzymatic equations were sometimes modified to accommodate specific characteristics of some substrates. For example, PP, upon cleavage generates two phosphate products, rather than the one phosphate product as generated by pNPP or 4MUP. Therefore, $d[P]_t/dt$ was multiplied by 2. ADP, ATP and GTP can react multiple times and this was considered by multiplying $[S]_0$ by the number of reactive groups. All experiments were done in triplicate.

Preparation of biotinylated AP. For most of this project, we used commercially prepared biotinylated AP. We also prepared our own biotinylated AP to explore lot-to-lot variation issues (used in Fig. 2d and Extended Data Figs. 5 and 6). For this, we used unconjugated AP from Rockland and a Biotin Protein Labeling Kit from Roche Diagnostics. To avoid unwanted side reactions, we removed Tris from the enzyme buffer with a Nanosep Centrifugal Device with Omega Membrane 30K from Pall Corporation by rinsing ten times. Then, we followed the manufacturer's instructions for the biotinylation kit by following 'Procedure 2: Polyclonal antibody' based on the mass of the protein.

Preparation of nanoantenna-AP covalent conjugate. AP was first diluted to 40 μ M using PBS buffer (pH7). Then, we added 3 equivalents of freshly prepared SPDP reagent (20 mM) in DMSO. AP was incubated with SPDP solution at room temperature for 30 min. Next, we used a Zeba spin desalting column to exchange the SPDP-modified protein reaction buffer for 10 mM HEPES, 150 mM NaCl, pH 8, and to remove reaction by-products and excess nonreacted SPDP reagent. Separately, we incubated the DNA nanoantenna (5' T 6-FAM, 3' SH) with 1 M dithiothreitol (DTT) in 40 μ l TE buffer for 30 min at 37°C. Then, we extracted with ethyl acetate and combined the aqueous phases. We then added 8 equivalents of reduced thiol DNA to the SPDP-modified AP and let it react for 1 h at room temperature. Note that to avoid side reactions, we used a DNA strand that did not contain guanine.

Presentation of data. Error bars on graphs and expressed values represent mean \pm s.e.m. for three distinct measurements. Typically, experiments were performed in triplicate, with the following exceptions: Extended Data Fig. 4h and Supplementary Fig. 7d for enzyme ratios not near the maximum, as well as Extended Data Fig. 4e,f

for covalent attachment of nanoantenna to AP, which had three injections of pNPP to the same sample. All MD simulations were performed once and all molecular docking simulations were performed ten times.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The fluorescence kinetic signatures of the substrates and inhibitors have been deposited on figshare (<https://doi.org/10.6084/m9.figshare.16798174>).

Code availability

The MATLAB fitting script for substrate kinetics is provided in the Supplementary Information.

References

- Perri, M. J. & Weber, S. H. Web-Based Job Submission Interface for the GAMESS Computational Chemistry Program. *J. Chem. Educ.* **91**, 2206–2208 (2014).
- Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res.* **39**, W270–W277 (2011).
- Grosdidier, A., Zoete, V. & Michielin, O. Fast docking using the CHARMM force field with EADock DSS. *J. Comput. Chem.* **32**, 2149–2159 (2011).
- Basu, S., Finke, A., Vera, L., Wang, M. & Olieric, V. Making routine native SAD a reality: lessons from beamline X06DA at the Swiss Light Source. *Acta Crystallogr. D Struct. Biol.* **75**, 262–271 (2019).
- Weissig, H., Schildge, A., Hoylaerts, M. F., Iqbal, M. & Millán, J. L. Cloning and expression of the bovine intestinal alkaline phosphatase gene: biochemical characterization of the recombinant enzyme. *Biochem. J.* **290**, 503–508 (1993).
- Llinas, P. et al. Structural studies of human placental alkaline phosphatase in complex with functional ligands. *J. Mol. Biol.* **350**, 441–451 (2005).
- Harada, T. et al. Characterization of structural and catalytic differences in rat intestinal alkaline phosphatase isozymes. *FEBS J.* **272**, 2477–2486 (2005).
- Hanwell, M. D. et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. *J. Cheminformatics* **4**, 17 (2012).
- Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004).
- Molecular Operating Environment (MOE) v.2019.01 (Chemical Computing Group, 2019).
- Case, D. A. et al. Amber 2020 (University of California, San Francisco, 2020).

Acknowledgements

We acknowledge scholarships from the Natural Sciences and Engineering Research Council of Canada, NSERC (S.G.H., A.D.), Fonds de recherche du Québec–Nature et technologies, FRQNT (S.G.H., D.L.), Groupe de recherche universitaire sur le médicament, GRUM (S.G.H.) and Bourse du Fonds Wilrose Desrosiers et Pauline Dunn (S.G.H.). This work was funded by NSERC, grant numbers RGPIN-2020-06975, RGPIN-06403 (A.V.-B.), Canada Research Chairs, grant number 950-230012 (A.V.-B.) and Le regroupement québécois de recherche sur la fonction, l'ingénierie et les applications des protéines (PROTEO). We acknowledge past and present members of our laboratory for insightful discussions, particularly C. Prévost-Tremblay (Faculté de médecine, UdeM).

Author contributions

S.G.H. and A.V.-B. conceived and designed the study. S.G.H. performed all experiments and the molecular docking simulations. A.D. provided ideas in an early phase of the project. D.L. wrote and used the MATLAB script to extract enzyme kinetic parameters. M.C.C.J.C.E. performed molecular dynamics simulations. X.W. realized the synthesis of the nanoantenna-AP conjugate. S.G.H. and A.V.-B. created the figures and wrote the manuscript, which was then reviewed and edited by all of the authors. A.V.-B. provided project oversight and funding.

Competing interests

The authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41592-021-01355-5>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41592-021-01355-5>.


Correspondence and requests for materials should be addressed to Alexis Vallée-Bélisle.

Peer review information *Nature Methods* thanks the anonymous reviewers for their contribution to the peer review of this work. Rita Strack was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.


Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Progress of a typical enzymatic reaction. (a) The states of an enzyme typically present during the catalysis of a substrate: the enzyme and substrate(s) ($E + S$) are introduced, followed by formation of the enzyme-substrate complex intermediate (ES). Next is the transition state (ES^\ddagger), followed by the enzyme-product complex intermediate (EP), and finally the enzyme and released product(s) ($E + P$). (b) Representative changes with time in concentration of the substrate ($[S]$), product ($[P]$), enzyme ($[E]$) and enzyme-substrate complex ($[ES]$) are shown. See Supplementary Note 1 for further discussion of important studies of methods to detect the different states of AP.




Extended Data Fig. 2 | In contrast to L12, the 'no linker' L0 nanoantenna does not allow FAM to bind to unoccupied biotin-binding site on streptavidin nor reach the surface of bAP. (a) Effect of free biotin binding on the nanoantenna-SA platform for the L0 (left) and L12 (right) nanoantennas. **(b)** Effect of free biotin binding on the nanoantenna-SA-bAP complex for the L0 and L12 nanoantennas. Discussion: **(a)** When the L0 or L12 nanoantennas bind to SA, their FAM fluorescence is quenched. Next, free biotin is added in excess. The fluorescence of the L0 nanoantenna does not change because its FAM moiety cannot reach any unoccupied biotin-binding sites⁵⁸, thus it remains unaffected by biotin binding. In contrast, the fluorescence of the L12 nanoantenna increases because its longer length allows its FAM moiety to weakly bind at an unoccupied biotin-binding site until it is ejected by the incoming higher affinity biotin molecule^{55,56}. **(b)** The L0 and L12 nanoantennas bind to SA. bAP then binds to the nanoantenna-SA platform. Next, free biotin is added in excess. The fluorescence of the L0 nanoantenna does not change upon addition of bAP because its FAM moiety cannot reach the biotin-binding sites where bAP binds and it also cannot reach the surface of bAP. Subsequent addition of free biotin also does not change its fluorescence for the same reason as without bAP and because most sites are full. In contrast, the fluorescence of the L12 nanoantenna increases upon addition of bAP because its longer length allows its FAM moiety to weakly bind at another biotin-binding site until it is ejected by the incoming high affinity biotin moiety of bAP, thereby allowing it to interact with bAP. Subsequent addition of free biotin does not substantially increase its fluorescence, indicative that the FAM moieties do not remain at the biotin-binding sites of SA. The spike observed upon addition of pNPP confirms that bAP has not been ejected. Although this experiment does not determine whether FAM is now interacting with bAP or with another location on SA, other parts of this paper demonstrate its interaction with bAP (*for example*, measurement of catalytic function). Conditions: 150 nM nanoantenna, 50 nM SA and 100 nM bAP in 1000 nM biotin in 200 mM Tris, 300 mM NaCl, 1 mM MgCl₂, pH 7.0, 37 °C.




Extended Data Fig. 3 | Molecular dynamics (MD) simulation of a possible nanoantenna-SA-bAP complex. During the simulation, the nanoantenna locates the FAM dye closer to its binding site near the enzyme's substrate active site. See also Video 1.




Extended Data Fig. 4 | Fluorescence spikes only occur when there is a hydrolysis reaction and when the nanoantennas are close to the enzyme. (a) Typical nanoantenna fluorescence signal used to monitor pNPP hydrolysis. (b) Addition of the reaction products, p-nitrophenol (pNP) and inorganic phosphate (P_i), does not give a fluorescence spike because there is no hydrolysis reaction. (c) Using an enzyme without phosphatase activity and which will not hydrolyze pNPP (for example, biotinylated glucose oxidase, bGOx), does not give a fluorescence spike because there is no hydrolysis reaction. (d) Here, the 'Dummy' nanoantenna does not have the dye (that is, no FAM) but it is still attached to SA via its biotin, while the 'Global' nanoantenna has FAM but it is not biotinylated and instead is free in solution. Thus, the hydrolysis reaction of pNPP still occurs, but this system does not monitor it since there is essentially no FAM-bAP interaction. (e) Here, 3'-thiolated L12 ssDNA nanoantennas were covalently attached to the lysine residues of AP (NA-AP; see Online Methods section). This nanoantenna-AP conjugate displays a spike during pNPP hydrolysis similar to the nanoantenna-SA-bAP complex. Although several synthesis steps are involved, it may be desirable for applications for which one does not wish to use the biotin-streptavidin platform. Note that the power was reduced from 635 V to 450 V due to the high baseline. (f) As a control, unattached thiolated and unconjugated AP do not display a spike during pNPP hydrolysis. (g) Here, a commercially prepared conjugate of SA covalently attached to AP (SA-AP) was used. The kinetic signature is shown for the PolyT L24 nanoantenna binding to SA-AP that results in fluorescence quenching, followed by pNPP hydrolysis that results in a spike. (h) Without knowledge of the SA-AP molecular weight due to an unknown number of conjugated SAs added by the manufacturer, we instead optimized using SA-AP volume (1, 2, 3, 4, 5, 7 and 14 μ L SA-AP). All experiments were performed with $n=1$ biologically independent enzyme samples examined over 3 independent experiments near the apparent maximum (2 to 5 μ L) and 1 otherwise. Data are presented as mean values \pm SEM. Even after this simple optimization, however, the spike intensity during pNPP hydrolysis remains weaker compared to using the SA and bAP strategy. Overall, these results show that no matter which attachment strategy is used, and despite some being better than others, FAM will still find its binding site on the AP enzyme. Conditions: (a-d) 150 nM L12 PolyT nanoantenna, 50 nM SA, 150 nM bAP, (e,f) -40 nM nanoantenna-bAP conjugate and (g,h) 150 nM nanoantenna, 1 to 14 μ L SA-AP; 100 μ M pNPP in 200 mM Tris, 300 mM NaCl, 1 mM $MgCl_2$, pH 7.0, 37 $^{\circ}C$.



Extended Data Fig. 5 | Effect of various chemical modifiers near FAM on cDNA binding, SA binding, bAP binding, and pNPP hydrolysis. Here, we investigated whether various chemical modifications near the dye ('modifiers') could affect the fluorescence signal of FAM by changing its interaction with bAP. **(a)** We used the L12 ssDNA FAM nanoantenna (5' T 6-FAM) with a complementary strand containing the modifier located at the 3'-end. **(b)** For comparison, 1) is the cDNA without a modifier; 2) is the cDNA with phosphate; 3) is the cDNA with a hydrophobic C₁₆ alkane chain; 4) is the cDNA with a modifier that contains a disulfide that would normally be cleaved before use to provide thiol functionality; 5) is a cDNA with the cleaved thiol. **(c)** Example kinetic signatures and **(d)** summary of all results. In short, the SA and bAP binding steps display different intensities with each modifier, but nevertheless they are qualitatively similar in all cases (*that is*, signal up or signal down). The exception to this is the C₁₆ alkane chain, which results in fluorescence quenching when bAP binds. In all cases, the spike intensity during pNPP hydrolysis was similar. All experiments were performed with n=1 biologically independent enzyme samples examined over 3 independent experiments. Data are presented as mean values ± SEM. Conditions: 15 nM nanoantenna, 75 nM cDNA, 5 nM SA, 10 nM homemade bAP, 25 μM pNPP, pH 8.0, 100 mM Tris, 10 mM NaCl, 37 °C.




Extended Data Fig. 6 | Effect of FAM connection and isomer on SA binding, bAP binding, and pNPP hydrolysis. (a) In most of this study until this point, we used a L12 ssDNA nanoantenna with 5' thymine 6-carboxyfluorescein (5' T 6-FAM). Here, however, we also tested other FAM connections on the same DNA sequence: 5' 6-carboxyfluorescein (5' 6-FAM), 5' 5-carboxyfluorescein (5' 5-FAM) and 3' 5-carboxyfluorescein (3' 5-FAM). (b) Shown are the quenching of fluorescence upon SA binding, the increase of fluorescence upon bAP binding, and the transient fluorescence spike during pNPP hydrolysis. Despite the similar fluorescence emission of 5-FAM and 6-FAM when conjugated to DNA, the various FAM nanoantennas display different trends for protein binding and pNPP hydrolysis. These differences are likely due to how the chemical connection subtly affects FAM-bAP interaction. All experiments were performed with $n=1$ biologically independent enzyme samples examined over 3 independent experiments. Data are presented as mean values \pm SEM. Conditions: 15 nM nanoantenna, 5 nM SA, 10 nM homemade bAP, 30 μ M pNPP, pH 8.0, 100 mM Tris, 10 mM NaCl, 30 $^{\circ}$ C. PMT voltage = 800 V.




Extended Data Fig. 7 | See next page for caption.


Extended Data Fig. 7 | Molecular dynamics (MD) trajectories of dyes and/or substrate on AP. The 100 ns MD simulation of AP with or without a dye (FAM, CAL, Cy3) and with or without the substrate pNPP. We selected the lowest energy pose (see Supplementary Fig. 13) and the next lowest energy pose that does not overlap with it and that has the linker location exposed. Dyes and pNPP are circled for visual clarity. In all cases, we observed that pNPP remains bound at the active sites. For AP with FAM and with or without pNPP, the position of FAM remains unchanged. For AP with CAL and with or without pNPP, the CAL dye does not have a stable position in either case. For AP-Cy3 without pNPP, the Cy3 dye position does not change, but with pNPP bound, the dye position can change, and it even dissociates from the surface. We emphasize that these MD simulations represent a possible signaling mechanism (see main text), and not a definite proposal.



Extended Data Fig. 8 | Excitation and emission spectra of double-dye dsDNA nanoantenna (FAM-CAL) suggest dye stacking. The excitation spectra (dashed line) and emission spectra (solid line) of the formation of the double-dye dsDNA nanoantenna: starting with ssDNA, after binding of cDNA, after binding of SA, and after binding of bAP. In **(a)**, only the FAM dye is present, and excitation and emission of FAM wavelengths ($\lambda_{\text{em}} = 520$ nm and $\lambda_{\text{ex}} = 498$ nm) are relatively unaffected by the addition of the complementary DNA (of note, the dsDNA antenna displays little sensitivity to SA and bAP attachment relative to ssDNA nanoantennas, see Fig. 1). In **(b)**, only the CAL dye is present, and excitation and emission of CAL wavelengths ($\lambda_{\text{em}} = 561$ nm and $\lambda_{\text{ex}} = 540$ nm) are relatively unaffected by the addition of the complementary DNA. In **(c)** and **(d)**, both dyes were present after the cDNA step (*that is*, the systems were chemically identical), but **(c)** was measured with the FAM wavelengths and **(d)** with the CAL wavelengths. We observed that both the FAM and CAL excitation and emission spectra are drastically affected when proximal to the other dye. This remains true even following the addition of the SA and bAP proteins. This decrease of signal intensity is likely attributable to a contact-mediated quenching mechanism between the dyes⁶⁵. These dyes seem to remain stacked even after the nanoantenna has moved to SA and bAP.



Extended Data Fig. 9 | Comparison of methods and error. (a) Classic Michaelis-Menten method to determine k_{cat} and K_{M} values for the 4MUP substrate using the initial rates of 4MU product generation. (b) Nanoantenna 'one-shot' method to determine k_{cat} and K_{M} values using the FAM fluorescence spike obtained during 4MUP hydrolysis. The values determined using both methods displayed good agreement. This analysis was performed several months after our values obtained for 4MUP in Fig. 3, which also shows the reproducibility of the method. (c) We further compared the accuracy of the 'one-shot' nanoantenna method over a similar approach performed using the 4MU progress curve under the same conditions. We found that a 'one-shot' 4MU progress curve over-estimated both the k_{cat} and K_{M} of the enzyme-substrate system. See relevant literature for fitting of progress curves. Conditions were 100 mM Tris, 10 mM NaCl, pH 8.0, 37 °C; also 150 nM nanoantenna, 50 nM SA, 20 nM bAP, and 300 μM 4MUP in (b and c), and the same buffer and temperature but 37.5 nM nanoantenna, 12.5 nM SA, 5 nM bAP, and 2 μM , 5 μM , 10 μM , 20 μM , 40 μM , 80 μM , 140 μM or 350 μM 4MUP in (a). In the latter two, the concentration of bAP was reduced to facilitate measurement of low 4MUP concentrations, and the nanoantenna and SA concentrations were reduced proportionately. All experiments were performed with $n=1$ biologically independent enzyme samples examined over 3 independent experiments. (24 measurements for the classic Michaelis-Menten via initial rates and 3 each for the nanoantenna spike and product progress curve). Data are presented as mean values \pm SEM.



Extended Data Fig. 10 | Theoretical nanoantenna kinetic signatures for different types of inhibitors. Here, we generated the expected spike profile of a theoretical system with the parameters: $k_{\text{cat}} = 100 \text{ s}^{-1}$, $K_M = 10 \mu\text{M}$, $[\text{enzyme}] = 100 \text{ nM}$, $[\text{substrate}] = 1000 \mu\text{M}$, and $[\text{inhibitor}] = 125 \mu\text{M}$. Shown are the effects of (a) competitive inhibitors with $K_i = 100 \mu\text{M}$ and $K_i = 1 \mu\text{M}$, (b) uncompetitive inhibitor with $K_i = 100 \mu\text{M}$, and (c) non-competitive inhibitor with $K_i = 100 \mu\text{M}$.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Cary Eclipse: Scan (v1.2(147)), Kinetics (v1.2(146)), Thermal (v1.2(146)); SX20 Stopped Flow: Pro-Data SX (v2.5.1852.0)

Data analysis Data analysis and plotting: Excel (v2101), KaleidaGraph (v4.0), OriginPro (v9.0.0); Kinetic fitting: MATLAB (vR2019a); Docking, MD or DFT: Amber2020, Avogadro (v1.2.0), MOE2019 (v2019.0102), UCSF Chimera (v1.11); ViewDock tool, file type: Dock 4, 5 or 6); Molecular structure images and log D calculations: MarvinSketch (v18.9.0)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The fluorescent signature of all substrates (Fig. 3) and the effect of inhibitors on the fluorescent signature of the substrate amifostine (Fig. 4) are provided on figshare (DOI: 10.6084/m9.figshare.16798174).

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We employed triplicate measurements as this is typically the standard employed when performing enzymatic studies.
Data exclusions	No data were excluded.
Replication	Fluorescent nanoantenna experiments on the hydrolysis of pNPP were performed dozens of times on different days and under different conditions. For other substrates, inhibitors and antibodies, all experiments were replicated at least three times.
Randomization	This is not relevant to our study. All our attempts to replicate experiments led to similar results.
Blinding	Fitting of the data was performed by a different person than the one who collected the data, and was without detailed knowledge of the properties of the substrate or inhibitor employed.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	<i>Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).</i>
Research sample	<i>State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.</i>
Sampling strategy	<i>Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.</i>
Data collection	<i>Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.</i>
Timing	<i>Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.</i>
Data exclusions	<i>If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.</i>
Non-participation	<i>State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.</i>
Randomization	<i>If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.</i>

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	<i>Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.</i>
Research sample	<i>Describe the research sample (e.g. a group of tagged <i>Passer domesticus</i>, all <i>Stenocereus thurberi</i> within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and</i>

any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

Sampling strategy *Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.*

Data collection *Describe the data collection procedure, including who recorded the data and how.*

Timing and spatial scale *Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken*

Data exclusions *If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.*

Reproducibility *Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.*

Randomization *Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.*

Blinding *Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.*

Did the study involve field work? Yes No

Field work, collection and transport

Field conditions *Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).*

Location *State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).*

Access & import/export *Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).*

Disturbance *Describe any disturbance caused by the study and how it was minimized.*

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

- n/a Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Human research participants
- Clinical data
- Dual use research of concern

- n/a Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging

Antibodies

Antibodies used *Goat IgG, Rockland Immunochemicals, lot # 32090, catalogue # 005-0102-0010. VIROTROL SARS-CoV-2, Bio-Rad, Reactive for SARS-CoV-2 total IgG/IgM and IgG antibodies, human plasma based, lot # 390300, catalogue # 200300A. VIROCLEAR SARS-CoV-2, Bio-Rad, Non-reactive for SARS-CoV-2 total IgG/IgM and IgG antibodies, human plasma based, lot # 390600, catalogue # 200500.*

Validation *Goat IgG, Rockland Immunochemicals: "Goat IgG whole molecule was prepared from normal serum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above. Goat IgG whole molecule assayed by immunoelectrophoresis resulted in a single precipitin arc against anti-Goat IgG and anti-Goat Serum." Reference provided on website: Yamada, Y. et al. Efficient and high-speed transduction of an antibody into living cells using a multifunctional nanocarrier system to control intracellular trafficking. J. Pharm. Sci. 104, 2845-2854 (2015). <https://rockland-inc.com/Product.aspx?id=45482>*

VIROTROL SARS-CoV-2 and VIROCLEAR SARS-CoV-2, Bio-Rad:

"These products are unassayed quality controls designed to produce results within a target range established by each laboratory.

These products should be analyzed in the same manner as unknown specimens according to instructions supplied by the manufacturer of the test kit being used. Levels of reactivity and specific performance characteristics of these products will vary with different manufacturers' kits and assay procedures."

<https://www.bio-rad.com/webroot/web/pdf/cdg/literature/Q-1676-CE.pdf>

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	<i>State the source of each cell line used.</i>
Authentication	<i>Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.</i>
Mycoplasma contamination	<i>Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.</i>
Commonly misidentified lines (See ICLAC register)	<i>Name any commonly misidentified cell lines used in the study and provide a rationale for their use.</i>

Palaeontology and Archaeology

Specimen provenance	<i>Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).</i>
Specimen deposition	<i>Indicate where the specimens have been deposited to permit free access by other researchers.</i>
Dating methods	<i>If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.</i>
<input type="checkbox"/> Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.	
Ethics oversight	<i>Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.</i>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	<i>For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.</i>
Wild animals	<i>Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.</i>
Field-collected samples	<i>For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.</i>
Ethics oversight	<i>Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.</i>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	<i>Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."</i>
Recruitment	<i>Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.</i>
Ethics oversight	<i>Identify the organization(s) that approved the study protocol.</i>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	<i>Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.</i>
Study protocol	<i>Note where the full trial protocol can be accessed OR if not available, explain why.</i>
Data collection	<i>Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.</i>
Outcomes	<i>Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.</i>

Dual use research of concern

Policy information about [dual use research of concern](#)

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No	Yes	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Public health
<input checked="" type="checkbox"/>	<input type="checkbox"/>	National security
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crops and/or livestock
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Ecosystems
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Any other significant area

Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Demonstrate how to render a vaccine ineffective
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Confer resistance to therapeutically useful antibiotics or antiviral agents
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Enhance the virulence of a pathogen or render a nonpathogen virulent
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Increase transmissibility of a pathogen
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Alter the host range of a pathogen
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Enable evasion of diagnostic/detection modalities
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Enable the weaponization of a biological agent or toxin
<input checked="" type="checkbox"/>	<input type="checkbox"/>	Any other potentially harmful combination of experiments and agents

ChIP-seq

Data deposition

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	<i>For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.</i>
Files in database submission	<i>Provide a list of all files available in the database submission.</i>
Genome browser session (e.g. UCSC)	<i>Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.</i>

Methodology

Replicates	<i>Describe the experimental replicates, specifying number, type and replicate agreement.</i>
Sequencing depth	<i>Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and</i>

Sequencing depth	<i>whether they were paired- or single-end.</i>
Antibodies	<i>Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.</i>
Peak calling parameters	<i>Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.</i>
Data quality	<i>Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.</i>
Software	<i>Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.</i>

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	<i>Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.</i>
Instrument	<i>Identify the instrument used for data collection, specifying make and model number.</i>
Software	<i>Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.</i>
Cell population abundance	<i>Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.</i>
Gating strategy	<i>Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.</i>

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type	<i>Indicate task or resting state; event-related or block design.</i>
Design specifications	<i>Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.</i>
Behavioral performance measures	<i>State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).</i>

Acquisition

Imaging type(s)	<i>Specify: functional, structural, diffusion, perfusion.</i>
Field strength	<i>Specify in Tesla</i>
Sequence & imaging parameters	<i>Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.</i>
Area of acquisition	<i>State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.</i>
Diffusion MRI	<input type="checkbox"/> Used <input type="checkbox"/> Not used

Preprocessing

Preprocessing software	<i>Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).</i>
Normalization	<i>If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.</i>
Normalization template	<i>Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.</i>
Noise and artifact removal	<i>Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).</i>
Volume censoring	<i>Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.</i>

Statistical modeling & inference

Model type and settings	<i>Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).</i>
Effect(s) tested	<i>Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.</i>
Specify type of analysis:	<input type="checkbox"/> Whole brain <input type="checkbox"/> ROI-based <input type="checkbox"/> Both
Statistic type for inference (See Eklund et al. 2016)	<i>Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.</i>
Correction	<i>Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).</i>

Models & analysis

n/a	Involvement in the study
<input type="checkbox"/>	<input type="checkbox"/> Functional and/or effective connectivity
<input type="checkbox"/>	<input type="checkbox"/> Graph analysis
<input type="checkbox"/>	<input type="checkbox"/> Multivariate modeling or predictive analysis
Functional and/or effective connectivity	<i>Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).</i>
Graph analysis	<i>Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).</i>
Multivariate modeling and predictive analysis	<i>Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.</i>